Sarepta raising $325M; Astellas joins the big migration to Cambridge, MA

With its shares boosted by news of swelling revenue from its eteplirsen franchise in Duchenne muscular dystrophy, Sarepta has priced shares $SRPT for a $325 million raise. The biotech says it plans to use the cash for a variety of purposes, ranging from commercialization efforts to business development and clinical trials.

→ Astellas has joined the global migration of biopharma companies to Cambridge, MA. The Japanese pharma has taken a lease out on space in Cambridge, according to a report from the Boston Business Journal.

→ Duluth, GA-based Sebacia completed a $20 million Series D financing led by existing investors Versant Ventures, Domain Associates, Accuitive Medical Ventures and Partners Healthcare Innovation Fund. The cash will be used to develop a new acne treatment. Sebacia also closed a $16 million debt facility with Hercules Capital.

→ Gemphire Therapeutics $GEMP today announced that it has entered into a loan and security agreement with Silicon Valley Bank for a term loan of up to $15 million.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,600+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->